Odds ratios for clinical and radiological parameters and outcomes according to World Health Organization body mass index (BMI) categories
| Patients | Unadjusted OR (95% CI) | Adjusted# OR (95% CI) | |
| Clinical and radiological parameters | |||
| NT-proBNP >600 pg·mL−1 | |||
| BMI <18.5 kg·m−2 | 12 (42.8%) | 2.38 (1.09–5.18) | 2.62 (1.10–6.23) |
| BMI 18.5–24.9 kg·m−2 | 115 (24.0%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 162 (23.4%) | 0.97 (0.74–1.28) | 0.98 (0.74–1.31) |
| BMI 30.0–34.9 kg·m−2 | 124 (31.2%) | 1.44 (1.07–1.94) | 1.41 (1.03–1.93) |
| BMI 35.0–39.9 kg·m−2 | 50 (34.0%) | 1.64 (1.10–2.44) | 1.62 (91.06–2.48) |
| BMI >40 kg·m−2 | 41 (41.0%) | 2.21 (1.41–3.46) | 2.90 (1.79–4.70) |
| sPESI high risk | |||
| BMI <18.5 kg·m−2 | 21 (72.4%) | 2.52 (1.10–5.80) | 2.49 (1.08–5.75) |
| BMI 18.5–24.9 kg·m−2 | 251 (51.0%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 375 (52.4%) | 1.06 (0.84–1.33) | 1.11 (0.88–1.40) |
| BMI 30.0–34.9 kg·m−2 | 230 (55.7%) | 1.21 (0.93–1.57) | 1.23 (0.95–1.60) |
| BMI 35.0–39.9 kg·m−2 | 84 (54.5%) | 1.15 (0.80–1.66) | 1.13 (0.78–1.62) |
| BMI >40 kg·m−2 | 66 (63.5%) | 1.67 (1.08–2.58) | 1.55 (1.00–2.41) |
| Pulmonary trunk >29 mm | |||
| BMI <18.5 kg·m−2 | 8 (27.6%) | 1.39 (0.60–3.22) | 1.36 (0.56–3.28) |
| BMI 18.5–24.9 kg·m−2 | 106 (21.5%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 232 (32.4%) | 1.75 (1.34–2.28) | 1.66 (1.27–2.19) |
| BMI 30.0–34.9 kg·m−2 | 168 (40.7%) | 2.50 (1.87–3.34) | 2.44 (1.81–3.28) |
| BMI 35.0–39.9 kg·m−2 | 59 (38.3%) | 2.26 (1.53–3.34) | 2.37 (1.59–3.53) |
| BMI >40 kg·m−2 | 49 (47.1%) | 3.24 (2.09–5.04) | 4.32 (2.73–6.83) |
| RV/LV >1.0 | |||
| BMI <18.5 kg·m−2 | 4 (13.8%) | 0.45 (0.15–1.31) | 0.40 (0.13–1.12) |
| BMI 18.5–24.9 kg·m−2 | 130 (26.4%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 231 (32.3%) | 1.33 (1.03–1.71) | 1.31 (1.01–1.70) |
| BMI 30.0–34.9 kg·m−2 | 157 (38.0%) | 1.71 (1.29–2.27) | 1.66 (1.24–2.21) |
| BMI 35.0–39.9 kg·m−2 | 48 (31.2%) | 1.26 (0.85–1.88) | 1.24 (0.83–1.85) |
| BMI >40 kg·m−2 | 41 (39.4%) | 1.81 (1.17–2.81) | 2.12 (1.34–3.33) |
| Central embolus | |||
| BMI <18.5 kg·m−2 | 7 (24.1%) | 0.78 (0.33–1.86) | 0.75 (0.31–1.82) |
| BMI 18.5–24.9 kg·m−2 | 143 (29.1%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 234 (32.7%) | 1.19 (1.19–0.92) | 1.17 (0.91–1.50) |
| BMI 30.0–34.9 kg·m−2 | 167 (40.4%) | 1.66 (1.26–2.19) | 1.61 (1.22–2.13) |
| BMI 35.0–39.9 kg·m−2 | 62 (40.3%) | 1.65 (1.30–2.40) | 1.61 (1.10–2.36) |
| BMI >40 kg·m−2 | 49 (47.1%) | 2.17 (1.41–3.35) | 2.34 (1.51–3.62) |
| Concurrent DVT | |||
| BMI <18.5 kg·m−2 | 3 (10.3%) | 0.44 (0.13–1.49) | 0.45 (0.13–1.52) |
| BMI 18.5–24.9 kg·m−2 | 102 (20.7%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 170 (23.7%) | 1.19 (0.90–1.57) | 1.15 (0.87–1.52) |
| BMI 30.0–34.9 kg·m−2 | 121 (29.3%) | 1.58 (1.17–2.15) | 1.57 (1.16–2.14) |
| BMI 35.0–39.9 kg·m−2 | 36 (23.4%) | 1.17 (0.76–1.80) | 1.20 (0.78–1.85) |
| BMI >40 kg·m−2 | 15 (14%) | 0.64 (0.36–1.16) | 0.68 (0.38–1.23) |
| Outcomes | |||
| Death | |||
| BMI <18.5 kg·m−2 | 1 (3.4%) | 1.22 (0.16–9.61) | 0.92 (0.11–7.59) |
| BMI 18.5–24.9 kg·m−2 | 14 (2.8%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 22 (3.1%) | 1.08 (0.55–2.14) | 1.09 (0.55–2.18) |
| BMI 30.0–34.9 kg·m−2 | 14 (3.4%) | 1.20 (0.56–2.54) | 1.21 (0.57–2.60) |
| BMI 35.0–39.9 kg·m−2 | 5 (3.2%) | 1.15 (0.41–3.23) | 1.29 (0.45–3.71) |
| BMI >40 kg·m−2 | 1 (1.0%) | 0.33 (0.04–2.55) | 0.53 (0.07–4.18) |
| Recurrent VTE | |||
| BMI <18.5 kg·m−2 | 1 (3.4%) | 1.92 (0.24–15.67) | 1.90 (0.23–15.57) |
| BMI 18.5–24.9 kg·m−2 | 9 (1.8%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 21 (2.9%) | 1.62 (0.74–3.57) | 1.55 (0.70–3.42) |
| BMI 30.0–34.9 kg·m−2 | 14 (3.4%) | 1.88 (0.81–4.40) | 1.82 (0.78–4.25) |
| BMI 35.0–39.9 kg·m−2 | 2 (1.3%) | 0.71 (0.15–3.30) | 0.71 (0.15–3.34) |
| BMI >40 kg·m−2 | 3 (2.9%) | 1.59 (0.42–5.99) | 1.41 (0.78–2.53) |
| Hospitalisation | |||
| BMI <18.5 kg·m−2 | 0 (0%) | 0 | 0 |
| BMI 18.5–24.9 kg·m−2 | 16 (3.3%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 34 (4.7%) | 1.48 (0.81–2.72) | 1.49 (0.81–2.75) |
| BMI 30.0–34.9 kg·m−2 | 23 (5.6%) | 1.75 (0.91–3.37) | 1.74 (0.90–3.35) |
| BMI 35.0–39.9 kg·m−2 | 11 (7.1%) | 2.29 (1.04–5.04) | 2.39 (1.08–5.32) |
| BMI >40 kg·m−2 | 5 (4.8%) | 1.50 (0.54–4.20) | 1.99 (0.70–5.67) |
| Bleeding | |||
| BMI <18.5 kg·m−2 | 0 (0%) | 0 | 0 |
| BMI 18.5–24.9 kg·m−2 | 3 (0.6%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 7 (1.0%) | 1.61 (0.41–6.25) | 1.72 (0.44–6.74) |
| BMI 30.0–34.9 kg·m−2 | 9 (2.2%) | 3.63 (0.98–13.50) | 3.82 (1.02–14.34) |
| BMI 35.0–39.9 kg·m−2 | 8 (5.2%) | 8.93 (2.34–34.10) | 9.99 (2.56–38.92) |
| BMI >40 kg·m−2 | 3 (2.9%) | 4.84 (0.96–24.33) | 7.26 (1.37–38.32) |
| All adverse events | |||
| BMI <18.5 kg·m−2 | 2 (6.9%) | 1.23 (0.279–5.43) | 1.08 (0.24–4.90) |
| BMI 18.5–24.9 kg·m−2 | 28 (5.7%) | 1 (ref.) | 1 (ref.) |
| BMI 25.0–29.9 kg·m−2 | 47 (6.6%) | 1.16 (0.72–1.89) | 1.15 (0.70–1.87) |
| BMI 30.0–34.9 kg·m−2 | 35 (8.5%) | 1.53 (0.92–2.57) | 1.50 (0.89–2.52) |
| BMI 35.0–39.9 kg·m−2 | 12 (7.8%) | 1.40 (0.69–2.83) | 1.47 (0.71–2.94) |
| BMI >40 kg·m−2 | 7 (6.7%) | 1.20 (0.51–2.82) | 1.55 (0.65–3.72) |
BMI <18.5 kg·m−2, n=29; 18.5–24.9 kg·m−2, n=492; 25.0–29.9 kg·m−2, n=716; 30.0–34.9 kg·m−2, n=413; 35.0–39.9 kg·m−2, n=154; >40 kg·m−2, n=104. Ref.: BMI 18.5–24.9 kg·m−2. Proportion was calculated per BMI category with follow-up up to 12 months. NT-proBNP: N-terminal pro-brain natriuretic peptide; sPESI: simplified Pulmonary Embolism Severity Index; RV/LV: right ventricular/left ventricular ratio; DVT: deep vein thrombosis; VTE: venous thromboembolism. #: for age and sex; sPESI only adjusted for sex.